Our IMP 3 ACT™ platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning ("ML") and artificial intelligence ("AI") tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs.
Partnerships Gates Foundation (grant for nasally inhaled peptide conjugate pan-coronavirus antiviral inhibitor); Johnson & Johnson / Blue Knight (Quickfire grants for pan-coronavirus inhibitor studies)
Indications
respiratory viruses (coronavirus)(Stage not disclosed)
Catalysts
— None
Status note Pre-clinical stage; no products approved. IMP3ACT platform designed to generate designable multi-antivirals (D-MAVs) extensible to new viral threats.
SP-3164
Stage not disclosed · ActiveModality: small molecule
Target cereblon
Indications
not disclosed(Stage not disclosed)
Status note Targeted protein degrader; legacy Salarius asset. Company plans to integrate SP-3164 into peptide-based PROTACs (P-PROTACs).
seclidemstat
Stage not disclosed · ActiveModality: small molecule
Aliases SP-2577
Target LSD1
Partnerships The University of Texas MD Anderson Cancer Center (investigator-sponsored trial)
Indications
Ewing sarcoma(Stage not disclosed)
myelodysplastic syndromes / chronic myelomonocytic leukemia (investigator-sponsored)(Stage not disclosed)
Status note Targeted protein inhibitor; FDA fast track designation for Ewing sarcoma. MDACC-sponsored trial of seclidemstat + azacytidine in MDS/CMML supported through December 2025; no further enrollment planned. Company seeking strategic alternatives including potential out-licensing.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.